| ★ |  Metreleptin-Neutralizing Antibodies Do Not Impact Treatment Outcomes in Generalized Lipodystrophy | | 40 | Estados Unidos | |
| 9 |  GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals | Metabolic Mind @metabolicmind | 49.3K | Estados Unidos | 87 |
| 19 |  Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS | | 4.3K | Estados Unidos | 86 |
| 11 |  Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight | | 1.1K | Estados Unidos | 87 |
| 6 |  GLP-1 Therapies: Where We’ve Been & Where We’re Going | Conversations on Health Care @cohcpodcast | 541 | Estados Unidos | 87 |
| 12 |  Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss | | 533 | Estados Unidos | 87 |
| 20 |  Berobenatide Monthly GLP-1 Injectable Shows Promise for Weight Loss | | 250 | Estados Unidos | 86 |
| 17 |  Diabetes Dialogue: Weekly Insulin Icodec Now Available for Type 2 Diabetes | | 206 | Estados Unidos | 86 |
| 5 |  Rapid Evolution in GLP-1s and Therapeutics at ADA 2026 | | 171 | Estados Unidos | 87 |
| 13 |  Diabetes Dialogue: Tegoprubart and Freedom from Insulin in Type 1 Diabetes | | 143 | Estados Unidos | 86 |
| 16 |  Diabetes Dialogue: CONNECT, TRANSCEND, and TRIUMPH at ADA 2026 | | 114 | Estados Unidos | 86 |
| 8 |  Incretins, Monitors, and Insulin Titration at ADA 2026 | | 76 | Estados Unidos | 87 |
| 18 |  Secret Shopper Study Reveals GLP-1 Telehealth Gaps | | 70 | Estados Unidos | 86 |
| 2 |  Synergy Between Metreleptin and GLP-1 Receptor Agonists in Lipodystrophy Real-World Data Suggest | | 68 | Estados Unidos | 91 |
| 7 |  GLP-1 Discontinuation in Type 2 Diabetes: What Happens When Patients Stop? | | 64 | Estados Unidos | 87 |
| 3 |  METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy | | 57 | Estados Unidos | 91 |
| 14 |  #62: GLP-1s: Life-Changing Results… at What Cost? | Live Long and Well With Dr. Bobby @drbobbylivelongandwell | 56 | Estados Unidos | 86 |
| 1 |  Implications of the Phase 4 Trial of Metreleptin in Patients With General Lipodystrophy | | 55 | Estados Unidos | 95 |
| 4 |  When to Add GLP-1 Receptor Agonists to Metreleptin in Lipodystrophy, With Lindsay Fourman, MD | | 44 | Estados Unidos | 90 |
| 10 |  Continuous Ketone Monitoring May Guide SGLT2i Use in T1D | | 33 | Estados Unidos | 87 |
| 15 |  Structuring Obesity Trials to Optimize Patient Retention and Data Integrity | | 18 | Estados Unidos | 86 |